Kilroy Realty has opened a second phase of its Oyster Point life sciences campus — but it's attracting financial and tech ...

The next phase of Kilroy's big Oyster Point project is seeing interest from tech and financial services as well as biotech, long the dominant industry in South San Francisco.

Thanks to robust demand for office spaces from global firms, the city's office stock has more than tripled since 2014.

LYON, France, Feb. 11, 2025 /CNW/ -- Ziwig, a French biotech company committed to advancing women's health, announces the ...

Oncotelic Therapeutics, a leader in RNA-based therapeutics, is pleased to announce that Vuong Trieu, Ph.D., Chairman & CEO, will be delivering a featured presentation at the SWCR 2025 Conference on ...

SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare ...

Q4 2024 Earnings Call Transcript February 6, 2025 IQVIA Holdings Inc. beats earnings expectations. Reported EPS is $3.12, ...

Researchers in Colorado are using words like “catastrophic” and “bombshell” to describe the potential impact of the 15 ...

Cancer researchers are one step closer to developing an effective vaccine to treat people with clear cell renal cell ...

AstraZeneca’s planned vaccine hub for Liverpool is off the table - business editor Karl Matchett and Whitehall editor Kate ...

Mexico’s bold plan to transform its food system toward healthier, more sustainably produced foods that support rural ...

Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC. Amezalpat builds momentum with both Fast Track and Orphan Drug Designations.